Skip to content
  • Home
  • Archives
  • 新冠COVID
    • 佐剂 Adjuvant
    • 疫苗文献 Vaccine Publications
    • 研发时间线 R&D Timeline
  • Research
    • Healthcare Sector Valuation
    • Biotechnology Equity Research
    • Introduction to FDA
    • esB/R Framework
    • Insider Selling Victims
    • Patent Litigation
    • Cases
    • Resources
    • Biotech IBB/XBI Gap Scan
    • Log
  • Tools
    • GapDB Gap Checker
    • Trialert
    • iPyNb Viewer
    • iPyTerm
  • P.S.I.C. Investment Club 正链投资
    • The Club
    • Team
  • Bookshelf
    • Qiu Guolu Series on Value Investing
  • Contact Us

hcp-mel-efficacy-vector-three

Published on October 23, 2016 in Dynavax SD-101 Early Clinical Data: Efficacy Analysis with Small Cohort of PatientsFull resolution (475 × 267)
Keytruda has 33% Overall Response Rate in Melanoma

Keytruda has 33% Overall Response Rate in Melanoma

Keytruda has 33% Overall Response Rate in Melanoma

Buffett FAQ eBook: His Wisdom in Q&A Format

Buffett’s answers to 463 questions covering 17 categories from “Investing approaches” to “Personal”. Complied by Nick Webb. Ebook Proudly Presented by BioEquity.org with Nick's authorization.

Bioequity Tools

  • DeepKinase 旦白志
  • GapDB Gap Checker
  • Global Life Science Map
  • iPyNbViewer
  • TRIALERT

Meta

  • Log in
  • Entries feed
  • Comments feed
  • WordPress.org

Archives

  • January 2021
  • November 2020
  • September 2020
  • October 2019
  • August 2019
  • January 2019
  • November 2018
  • August 2018
  • May 2018
  • April 2018
  • February 2018
  • January 2018
  • December 2017
  • November 2017
  • October 2017
  • August 2017
  • June 2017
  • April 2017
  • March 2017
  • December 2016
  • November 2016
  • October 2016
  • September 2016
  • August 2016
  • June 2016
  • April 2016
  • December 2015
  • October 2015
  • September 2015
  • August 2015
  • July 2015
  • May 2015
  • April 2015
  • February 2015
  • December 2014
  • October 2014
  • September 2014
  • August 2014
  • May 2014
  • February 2014
  • December 2013
  • November 2013
  • October 2013
  • July 2013
  • January 2013
  • November 2012
  • August 2012

Categories

  • BigMarket
  • Books
  • Career
  • For fun
  • PSIC
  • Quantitative Analysis
  • Research
  • Tools
  • Trading
  • 中文 In Chinese

Disclaimer

pStrand and bioequity.org website is NOT an investment adviser, for any investing or trading decisions, always consult your financial adviser first. The information on this website is solely an opinion about stocks, market trends or conditions by pStrand (BioEquity.org). Under no circumstances should any content or materials on this website be used, interpreted as, or deemed to be a recommendation to any investor as an offer or a solicitation of an offer to buy, sell, or issue any interest, securities or instruments of any issuer. Any investment decisions must in all cases be made by the reader or by his or her investment adviser. pStrand (BioEquity.org) may or may not have long and/or short positions in the securities or derivatives of companies mentioned and may or may not take the positions discussed.
Proudly powered by WordPress